Tagged with HAL

China With nearly half of Chinese adults now suffering from myopia and age-related eye conditions on the rise, China is on the brink of an ophthalmology boom — a market set to more than double by 2031. While global players like Santen have taken an early lead, a new wave of…

China Ye Liu, CEO and cofounder of OcuMension Therapeutics, speaks about the challenges and triumphs of running one of China’s most ambitious ophthalmology-focused biopharmaceutical companies. Launched with USD 5 million and no initial products, OcuMension now leads in China’s ophthalmology drug development, maintains rapid growth, and is preparing for global reach.…

Germany A summary of some of the top stories coming out of Germany’s biopharma industry, including Bayer’s EMA win for its Eylea eye therapy; the oncology deal Merck KGaA has cut with SpringWorks Therapeutics; the bispecific antibody alliance between BMS and BioNTech, and Sartorius’ acquisition of microtissue firm MatTek.   Bayer…

UK A roundup of the biggest UK pharma news, including the industry’s uncertain position after the UK-US trade accord; Haleon’s full takeover of its Chinese joint venture; AstraZeneca’s acquisition of Belgian biotech EsoBiotec and its exit from neuroscience; GSK’s liver disease asset deal with Boston Pharmaceuticals, and CellCentric’s US expansion.  …

Saudi Arabia Mohamed Ayad, representing Santen as the Head of the Middle East, discusses the Japanese multinational firm’s growing presence and strategic focus in the region. He shares insights into the challenges and opportunities within the eye health care and ophthalmology market, Santen’s innovative approach to product offerings, and the company’s commitment…

Saudi Arabia Ali ElAkkad, General Manager of Bausch & Lomb Pharma and Consumer for the Middle East and Pakistan, shares insights into the company’s strategic priorities and its commitment to innovation in the region. He discusses how Bausch & Lomb is focusing on bringing high-quality ophthalmology products to market, fostering a high-performance…

Saudi Arabia Saudi Arabia is rapidly transforming into a key battleground for the consumer healthcare industry, and Haleon is positioning itself at the forefront of this shift. With a growing appetite for innovation, a highly engaged consumer base, and a regulatory landscape that demands agility, the company is reshaping its strategy to…

Saudi Arabia Alcon’s Fadi AlSafadi shares his insights on the evolving eye care landscape in the dynamic Middle East and Africa region. He discusses Alcon’s innovative initiatives, including advancements in digitalisation, sustainability efforts, and their approach to enhancing accessibility and education. AlSafadi also highlights Alcon’s commitment to improving healthcare outcomes, fostering local…

Japan Santen is on a mission to reshape the future of eye health. With three major product launches ahead, bold biotech deals, and a revamped global strategy, the Japanese pharma is doubling down on its ophthalmology dominance. Fresh off a transformational reorganization and a landmark myopia approval, Santen is proving that…

Mexico Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact is enormous. Rare disease patients, for example, often face delayed diagnoses, limited treatment options, and a lack of specialised care compared to those suffering from more common…

China Eye health, despite being essential for most of us in our daily lives, receives significantly less research funding than fields like cancer or diabetes. According to IQVIA, global spending on oncology is expected to reach USD 440 billion by 2028, while ophthalmology will see just USD 38 billion. However, conditions…

China Shawn Xiang, corporate officer and China head at Santen, discusses the eye care specialist’s second-largest market and the challenges of diagnosing and managing eye conditions in China where a lack of public awareness is coupled with the country’s shortage of clinical capacity in ophthalmology. He remarks on Santen’s “China 2.0”…